Skip to content

Trial · Interventional

CompletedPhase 3Results postedRegistry data

Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm

NCTNCT00163189 (opens ClinicalTrials.gov in a new tab)Other idA6281271Other id2004-002992-17Other id2004

Overview

Status
Completed
Phase
Phase 3
Enrollment
98 participants (actual)
Sponsor
Pfizer · Industry
Design
Allocation not applicable · Open label (no masking)
Countries
1 country

France

Start
Jan 2005
Primary completion
Dec 2014
Completion
Dec 2014
First posted
13 Sept 2005 (estimated)
Last update posted
21 Feb 2024
Conditions
Growth Hormone Deficiency

Timeline

1 trial · 1 completed · 1 with posted results

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
20062008201020122014
  1. Ph 3

    Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm

    NCT00163189

    Jan 2005 to Dec 2014

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

To estimate the evolution of height and growth rate over 5 years of growth hormone (GH) treatment To estimate the prognostic factors of growth rate with GH treatment To confirm the good clinical and biological safety of GH treatment in such children

Interventions

  • SomatropinDrug

Arms1

  • Experimental

    Somatropin

Primary outcomes2

Outcomes the sponsor listed as primary.

  1. Change From Baseline in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Month 36: Full Analysis Population

    Time frame · Baseline, Month 36

    Registry description

    Height was measured using a wall mounted device (example, Harpenden stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded. Height SDS CA Yx = (height Yx - reference mean for CA Yx) / reference SD for CA Yx; Yx refers to the value at particular timepoint x. Height in SDS was calculated using Sempe reference means and SD for height. CA calculated as integer (Date of height measurement-Date of birth)/365.25\*12.

  2. Change From Baseline in Height Standard Deviation Score (SD) for Chronological Age (CA) at Month 36: Per Protocol (PP) Population

    Time frame · Baseline, Month 36

    Registry description

    Height was measured using a wall mounted device (example, Harpenden stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded. Height SDS CA Yx = (height Yx - reference mean for CA Yx) / reference SD for CA Yx; Yx refers to the value at particular timepoint x. Height in SDS was calculated using Sempe reference means and SD for height. CA calculated as integer (Date of height measurement-Date of birth)/365.25\*12.

Secondary outcomes(11)
  1. Mean Height

    Time frame · Baseline, Month 12, 24, 36, 48, 60

    Registry description

    The standing height measurements were performed using a wall mounted device (example Harpenden Stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded.

  2. Mean Height Standard Deviation Score (SDS) for Bone Age (BA)

    Time frame · Baseline, Month 12, 24, 36, 48, 60

    Registry description

    The standing height measurements were performed using a wall mounted device (example Harpenden Stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded. Height SDS BA Yx = (height Yx - reference mean for BA Yx) / reference SD for BA Yx; Yx refers to the value at particular timepoint x. Height in SDS was calculated using Sempe reference means and SD for height. BA was estimated locally using an X-ray from the left wrist and hand.

  3. Annual Growth Rate (AGR)

    Time frame · Baseline, Month 12, 24, 36, 48, 60

    Registry description

    AGR at Yx was derived by subtracting AGR at baseline from Yx value. AGR was calculated each year and re scaled to 1 year if the interval between Yx and Y\[x-1\] was not 365 days, as long as a participant remained in the study. AGR at Yx was calculated using the previous height measurements (Y\[x-1\]) and height recorded at Yx (AGR Yx = \[height Yx-height Y{x-1}\] / (\[date of Yx - date of Y{x-1}\] /365.25). Yx refers to the value at particular timepoint x.

  4. Growth Rate (GR) Standard Deviation Score (SDS) for Bone Age (BA)

    Time frame · Month 12, 24, 36, 48, 60

    Registry description

    GR SDS BA Yx = (GR Yx - reference mean for BA Yx) / reference SD for BA Yx; Yx refers to the value at particular timepoint x. GR in SDS was calculated using Sempe reference means and SD for GR. BA was estimated locally using an X-ray from the left wrist and hand.

  5. Growth Rate (GR) Standard Deviation Score (SDS) for Chronological Age (CA)

    Time frame · Baseline, Month 12, 24, 36, 48, 60

    Registry description

    GR SDS CA Yx = (GR Yx - reference mean for CA Yx) / reference SD for CA Yx; Yx refers to the value at particular timepoint x. GR in SDS was calculated using Sempe reference means and SD for GR. CA calculated as integer (Date of height measurement-Date of birth)/365.25\*12.

  6. Body Mass Index (BMI)

    Time frame · Baseline, Month 12, 24, 36, 48, 60

    Registry description

    BMI was calculated by weight divided by height squared and measured as kilogram per square meter (kg/m\^2).

  7. Change From Baseline in Height at Month 12, 24, 36, 48 and 60

    Time frame · Baseline, Month 12, 24, 36, 48, 60

    Registry description

    The standing height measurements were performed using a wall mounted device (example Harpenden Stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded.

  8. Change From Baseline in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Month 12, 24, 48 and 60

    Time frame · Baseline, Month 12, 24, 48, 60

    Registry description

    The standing height measurements were performed using a wall mounted device (example Harpenden Stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded. Height SDS CA Yx = (height Yx - reference mean for CA Yx) / reference SD for CA Yx; Yx refers to the value at particular timepoint x. Height in SDS was calculated using Sempe reference means and SD for height. CA calculated as integer (Date of height measurement-Date of birth)/365.25\*12.

  9. Change From Baseline in Height Standard Deviation Score (SDS) for Bone Age (BA) at Month 12, 24, 36, 48 and 60

    Time frame · Baseline, Month 12, 24, 36, 48, 60

    Registry description

    The standing height measurements were performed using a wall mounted device (example Harpenden Stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded. Height SDS BA Yx = (height Yx - reference mean for BA Yx) / reference SD for BA Yx; Yx refers to the value at particular timepoint x. Height in SDS was calculated using Sempe reference means and SD for height. BA was estimated locally using an X-ray from the left wrist and hand.

  10. Change From Baseline in Bone Age (BA) at Month 12, 24, 36, 48 and 60

    Time frame · Baseline, Month 12, 24, 36, 48, 60

    Registry description

    BA was estimated locally using an X-ray from the left wrist and hand.

  11. Ratio of Bone Age (BA) to Chronological Age (CA)

    Time frame · Baseline, Month 12, 24, 36, 48, 60

    Registry description

    BA was estimated locally using an X-ray from the left wrist and hand. CA at the date of corresponding X-ray (Date of X-ray - Date of birth)/365.25. Ratio of BA/CA at each annual study visit was calculated.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

Primary outcome results

Primary outcomeMean· Baseline, Month 36

Change From Baseline in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Month 36: Full Analysis Population

GroupValue (Standard Deviation Score (SDS))Spread
Genotonorm-2.911.19
Primary outcomeMean· Baseline, Month 36

Change From Baseline in Height Standard Deviation Score (SD) for Chronological Age (CA) at Month 36: Per Protocol (PP) Population

GroupValue (SDS)Spread
Genotonorm-2.860.89
Secondary and other outcome results(6)
Secondary outcomeMean· Baseline, Month 12, 24, 36, 48, 60

Mean Height

GroupValue (centimeters (cm))Spread
Genotonorm133.915.7
Secondary outcomeMean· Baseline, Month 12, 24, 36, 48, 60

Mean Height Standard Deviation Score (SDS) for Bone Age (BA)

GroupValue (SDS)Spread
Genotonorm-0.291.15
Secondary outcomeMean· Baseline, Month 12, 24, 36, 48, 60

Annual Growth Rate (AGR)

GroupValue (cm/year)Spread
Genotonorm3.02.0
Secondary outcomeMean· Month 12, 24, 36, 48, 60

Growth Rate (GR) Standard Deviation Score (SDS) for Bone Age (BA)

GroupValue (SDS)Spread
Genotonorm-0.132.15
Secondary outcomeMean· Baseline, Month 12, 24, 36, 48, 60

Growth Rate (GR) Standard Deviation Score (SDS) for Chronological Age (CA)

GroupValue (SDS)Spread
Genotonorm-2.042.03
Secondary outcomeMean· Baseline, Month 12, 24, 36, 48, 60

Body Mass Index (BMI)

GroupValue (kg/m^2)Spread
Genotonorm19.43.6

Adverse events, as posted

Adverse events as posted: participants affected out of participants at risk, by group
GroupDeathsSerious eventsOther events
GenotonormGenotonorm 0.46 milligram per kilogram (mg/kg) administered weekly, divided into 7 daily subcutaneous injections (maximum dose not exceeding 50 microgram \[mcg\]/kg/day) for up to 60 months.–45 / 9881 / 98

Each cell reads participants affected / participants at risk, as the registry posted them.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies1

Studies that cite this trial.

More studies

1 study on this page

Indexing hint: Clinical trial · 2019

Efficacy and safety of recombinant growth hormone treatment in children with growth retardation related to long-term glucocorticosteroid therapy.

Basmaison et al. 2019Annales d'endocrinologiecited by 3

PMID 30910221DOI 10.1016/j.ando.2019.02.001PUB-30910221

Full text at the publisher
Publisher page

Eligibility

Who could join, as posted.

Sex
All
Age
Not stated
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Glucocorticosteroid treatment for 12 months at least * Bone age \< 15 years for a boy and \< 13 years for a girl * Child measured height \< - 2 SD, Child currently treated by GH Exclusion Criteria: * Known diabetes (type 1 or type 2) * A previous history of intolerance or hypersensitivity to the study drug or to drugs with similar chemical structures

PepBank is a research reference. Talk to a doctor before you use any peptide.